Achieve Life Sciences outlines first half 2027 cytisinicline launch supported by US manufacturing shift and AI-driven commercialization
Earnings Call Insights: Achieve Life Sciences (ACHV) Q4 2025 Management View Richard A. Stewart, President, CEO & Executive Director, emphasized the company’s transition from a clinical-stage to a commercially focused enterprise following the NDA submission in June 2025, stating, “Our primary objective now is to make cytisinicline available to the 25 million patients who smoke … Read more